← ANALYST RATINGS · TIPRANKS
Harrow Health (HROW): analyst forecast and price target
Analyst consensus
Strong Buy8 Buy0 Hold0 Sell
Ratings of 8 analysts in the last 3 months12-month forecast
Based on 8 price targets given in the last 3 months, the average target is $64.33, the highest $88.00, the lowest $45.00. The average is +135.8% from the last price of $27.28.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $31.00 → $28.00−9.7% | Hold | +2.6% | Reiterated | 15.10.26on TipRanks 02:05 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $31.00 → $27.00−12.9% | Hold | −1.0% | Reiterated | 15.10.26on TipRanks 02:05 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $30.00 → $27.00−10.0% | Hold | −1.0% | Reiterated | 15.10.26on TipRanks 02:05 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $30.00 → $26.00−13.3% | Hold | −4.7% | Reiterated | 15.10.26on TipRanks 02:05 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $31.00 → $28.00−9.7% | Hold | +2.6% | Reiterated | 15.10.26on TipRanks 02:05 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $31.00 → $28.00−9.7% | Hold | +2.6% | Reiterated | 15.10.26on TipRanks 02:05 | — | |
| Lachlan Hanbury Brown★★★★★★★★★★#11394 · hits 35% · avg −5.4% | William Blair | — | Buy | — | Reiterated | 05.10.26on TipRanks 10:55 | −0.3%next day −1.3% · 5 days −5.2% | ↗ |
| Thomas Flaten★★★★★★★★★★#1650 · hits 47% · avg +8.9% | Lake Street | $60.00 | Buy | +119.9% | Reiterated | 05.10.26on TipRanks 09:10 | −0.3%next day −1.3% · 5 days −5.2% | ↗ |
| Chase Knickerbocker★★★★★★★★★★#75 · hits 59% · avg +36.2% | Craig-Hallum | — | Buy | — | Reiterated | 29.09.26on TipRanks Sep 30 05:10 | −0.4%next day −1.7% · 5 days −5.3% | ↗ |
| Daniel Clark★★★★★★★★★★#3492 · hits 65% · avg +17.4% | Leerink Partners | $45.00 | Buy | +65.0% | Initiated | 09.09.26on TipRanks 08:25 | −0.3%next day −2.0% · 5 days −7.8% | ↗ |
| Thomas Shrader★★★★★★★★★★#2198 · hits 39% · avg +6.6% | BTIG | $63.00 | Buy | +130.9% | Reiterated | 25.08.26on TipRanks Aug 26 06:50 | +3.5%next day −4.9% · 5 days −10.0% | ↗ |
| Yi Chen★★★★★★★★★★#10518 · hits 41% · avg −1.0% | H.C. Wainwright | $70.00 | Buy | +156.6% | Reiterated | 12.08.26on TipRanks 06:30 | −0.4%next day −1.9% · 5 days +6.2% | ↗ |
| Steven Seedhouse★★★★★★★★★★#1374 · hits 43% · avg +10.3% | Cantor Fitzgerald | $88.00 | Buy | +222.6% | Reiterated | 10.08.26on TipRanks Aug 11 09:26 | +0.7%next day −2.8% · 5 days −3.0% | ↗ |
| Mayank Mamtani★★★★★★★★★★#2653 · hits 38% · avg +5.8% | B. Riley Securities | $60.00 | Buy | +119.9% | Reiterated | 10.08.26on TipRanks 09:16 | +0.7%next day −2.8% · 5 days −3.0% | ↗ |
| Jeffrey Cohen★★★★★★★★★★#11115 · hits 35% · avg −2.9% | Ladenburg Thalmann & Co. | $62.00 | Buy | +127.3% | Reiterated | 04.03.26on TipRanks 07:45 | +0.9%next day −7.2% · 5 days −4.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Harrow Health
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $64.33 at a price of $30.80 (+108.9%); now: $64.33 at $27.28 (+135.8%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 15 | 8 | 7 | 5 | 3 | 4 |
| Buy | 7 | 7 | 10 | 14 | 13 | 9 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 16.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.19 (from $0.01 to $0.37). Last quarter: $-0.46.
Sales
Next quarter’s sales estimate — $98M (from $94M to $102M). Last quarter: $71M.
Best top-analyst consensus in the sector · Healthcare
About Harrow Health
- CEO: Mark L. Baum
- Employees: 373
- 1A Burton Hills Boulevard, Nashville, TN, 37215, US
- www.harrow.com
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
Data from the stock’s TipRanks forecast page, read 25 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗